Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. 

See our community guidelines: http://bit.ly/2kFA8hr

Oxford Finance LLC

General Atlantic

Rock Springs Capital

RTW Investments

WuXi AppTec

Bill & Melinda Gates Foundation

Terra Magnum Capital Partners (""""TMCP"""")""

CCB International

JDRF T1D Fund

BlackRock

Immunocore

Unhealthy cells have evolved mechanisms for evading T cells, making diseases like cancer harder to treat. 

ImmTAC molecules contain a T cell receptor that has been engineered to better recognise its target and seek out evading cells. #IMCRSharing #innovation

It is by living our values daily that we are able to develop transformative treatments and to innovate for patients. #WeAreIMCR #innovation #ResearchAndDevelopment

Looking to advance your career in Regulatory Affairs? Apply for our Regulatory Submissions Manager position and grow within a highly innovative, agile, and entrepreneurial environment. https://lnkd.in/eu7WxW_v #WeAreIMCR #hiring #biotechjobs

Gynecologic cancers account for nearly 40% of cancer cases & 1/3 of cancer deaths in women. We must continue the search for new treatments & prevention measures to save the lives of women across the globe. #CervicalCancerPreventionWeek #CervicalCancerAwarenessMonth #WeAreIMCR

Come and apply the principles of effective clinical project practices at a pioneering biotech. #WeAreIMCR #biotechjobs #hiring
https://lnkd.in/eTSVJJcC

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

COM:IMMUNOCORE

Immunocore Holdings plc

Last Close

32.42

21/11 21:00

Market Cap

1.90B

Beta: -

Volume Today

168.16K

Avg: -

Filings Not Available